Next Article in Journal / Special Issue
The Role of STAT3 in Thyroid Cancer
Previous Article in Journal
Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells
Previous Article in Special Issue
STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications
Open AccessReview

Genetic Interactions of STAT3 and Anticancer Drug Development

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Cancers 2014, 6(1), 494-525;
Received: 13 November 2013 / Revised: 18 February 2014 / Accepted: 20 February 2014 / Published: 6 March 2014
(This article belongs to the Special Issue STAT3 Signalling in Cancer: Friend or Foe)
Signal transducer and activator of transcription 3 (STAT3) plays critical roles in tumorigenesis and malignant evolution and has been intensively studied as a therapeutic target for cancer. A number of STAT3 inhibitors have been evaluated for their antitumor activity in vitro and in vivo in experimental tumor models and several approved therapeutic agents have been reported to function as STAT3 inhibitors. Nevertheless, most STAT3 inhibitors have yet to be translated to clinical evaluation for cancer treatment, presumably because of pharmacokinetic, efficacy, and safety issues. In fact, a major cause of failure of anticancer drug development is lack of efficacy. Genetic interactions among various cancer-related pathways often provide redundant input from parallel and/or cooperative pathways that drives and maintains survival environments for cancer cells, leading to low efficacy of single-target agents. Exploiting genetic interactions of STAT3 with other cancer-related pathways may provide molecular insight into mechanisms of cancer resistance to pathway-targeted therapies and strategies for development of more effective anticancer agents and treatment regimens. This review focuses on functional regulation of STAT3 activity; possible interactions of the STAT3, RAS, epidermal growth factor receptor, and reduction-oxidation pathways; and molecular mechanisms that modulate therapeutic efficacies of STAT3 inhibitors. View Full-Text
Keywords: genetic interaction; cancer; drug development; STAT3; Ras; EGFR; redox; reactive oxygen species; synthetic lethality genetic interaction; cancer; drug development; STAT3; Ras; EGFR; redox; reactive oxygen species; synthetic lethality
Show Figures

Figure 1

MDPI and ACS Style

Fang, B. Genetic Interactions of STAT3 and Anticancer Drug Development. Cancers 2014, 6, 494-525.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop